Analysts’ $156.67 Mean Target Implies 77.8% Upside for GeneDx
GeneDx Holdings Corp. shares have attracted nine analysts’ price targets averaging $156.67, implying a 77.8% upside from current levels, with estimates ranging from $130.00 to $177.00 and a standard deviation of $16.54. The Zacks Consensus Estimate for annual EPS rose 29.3% this month, earning a Zacks Rank #1.
1. Analyst Price Target Breakdown
Nine Wall Street analysts have set short-term price targets for GeneDx Holdings averaging $156.67, signaling a potential 77.8% gain. These targets span from $130.00 to $177.00 with a standard deviation of $16.54, indicating a relatively tight consensus on valuation expectations.
2. EPS Revisions and Zacks Ranking
The Zacks Consensus Estimate for GeneDx’s annual EPS climbed 29.3% over the past month, driven by at least one upward revision against no downgrades. This surge in estimates has propelled the company to a Zacks Rank #1 (Strong Buy), placing it among the top 5% of over 4,000 ranked stocks.
3. Implications and Cautions
While a clustered set of price targets can serve as a starting point for valuation, historical data shows that targets can be overly optimistic. Investors should weigh analyst optimism alongside fundamental drivers such as revenue growth, profit margins and upcoming clinical or regulatory milestones.